Description

Arixtra (Fondaparinux Natrium) Solution for Injections 12.5 mg/ml, 0.6 ml, №10 in Syringe

Composition:

Each 0.6 ml syringe contains 7.5 mg of Fondaparinux Natrium as the active ingredient.

Mechanism of Action:

Fondaparinux, a synthetic pentasaccharide, selectively inhibits factor Xa, preventing the conversion of prothrombin to thrombin. This action inhibits the coagulation cascade, reducing thrombus formation risk.

Pharmacological Properties:

Fondaparinux Natrium acts as an anticoagulant by specifically targeting factor Xa, contributing to the prevention of venous thromboembolic events.

Indications for Use:

Arixtra is indicated for the prevention of venous thromboembolic events in patients undergoing orthopedic surgery.

Contraindications:

Do not administer Arixtra to patients with active major bleeding or severe renal impairment (CrCl < 30 mL/min).

Side Effects:

Common side effects may include bleeding complications, bruising, and injection site reactions. Monitor for signs of bleeding disorders.

Usage Instructions:

The recommended dosage of Arixtra is 2.5 mg once daily administered by subcutaneous injection into the abdomen. Rotate injection sites for optimal absorption.

Benefits Compared to Analogues:

Arixtra offers a favorable safety profile and efficacy in preventing venous thromboembolism, particularly in orthopedic surgery patients, compared to traditional anticoagulants.

Suitable Patient Groups:

Arixtra is suitable for adult patients, including the elderly, undergoing orthopedic surgery. Caution is advised in patients with a history of heparin-induced thrombocytopenia.

Storage and Shelf Life:

Store Arixtra at the recommended temperature as per the packaging instructions. Check the expiration date before use and do not use expired medication.

Packaging Description:

Arixtra is available in pre-filled syringes containing 0.6 ml of solution, each syringe delivering 7.5 mg of Fondaparinux Natrium.

Clinical Evidence and Proven Effectiveness:

Fondaparinux has demonstrated efficacy in preventing venous thromboembolism in orthopedic surgery patients. Studies have shown its superiority over traditional anticoagulants like enoxaparin in specific surgical settings.

Arixtra has shown to be effective in reducing thrombotic events with a lower risk of bleeding complications, making it a valuable option for thromboprophylaxis.